Earnings, Opdivo Results Boost Bristol-Myers Stock

Fellow drug companies working on rival lung cancer treatments are falling

by Josh Selwayy

Published on Feb 5, 2018 at 10:11 AM

Bristol-Myers Squibb Co (NYSE:BMY) is trading up 1.4% today at $64.33, after the company posted better-than-expected earnings and said its blockbuster lung cancer treatment Opdivo -- in combination with its immunotherapy drug Yervoy -- met its goals in a late-stage study. Meanwhile, the news is pressuring shares of rival Merck (MRK), which makes a competing product. Despite these positive developments, BMY stock has yet to see any bullish attention from analysts.

In fact, the majority of covering analysts remain bearish on the security. Although Bristol-Myers sports seven "strong buy" ratings, nine other brokerage firms have "hold" or "strong sell" recommendations in place. The shares are also now trading above their average 12-month price target of $64.14. Considering all this, it wouldn't be surprising to see upgrades and/or price-target hikes come through on BMY.

It would seem options traders were betting bullishly coming into today, though. Call buying more than doubled put buying during the past two weeks at the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX), with the biggest increases in open interest occurring at the March 72.50 and 67.50 calls. The front-month February 62 call was also popular.

Looking at the charts, shares of Bristol-Myers Squibb have been bouncing mostly between $60 and $65 since late August, with a pullback earlier this month bottoming just above the 200-day moving average. Overall, BMY stock is up almost 27% year-over-year.

bmy stock price


A Schaeffer's exclusive

TOP STOCK PICKS 2020

Access your FREE insider report before it's too late!


 
 

Partnercenter


NEW! Explore Schaeffer’s Partners' deals and get connected to top online brokerages with deals tailored exclusively for our readers.  Get answers to your questions regarding transfer fees, commission rates, programs and available discounts related to online trading services.

MORE | MARKETstories


Former Hedge Fund Manager Makes $25,000 "Trading Breakthrough"
Click to continue to advertiser's site.
Fed Meeting Headlines Earnings-Packed Week
Several big blue-chip and FAANG names will enter the earnings confessional
Amphenol Stock Sees Bullish Attention Post-Earnings
APH put options have been popular
The IRS Loopholes Retirees Need to Know
Click to continue to advertiser's site.